제노티크 바이오사이언시즈(XBIO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.73 (+10.98%), 시가총액 $0.01B, 52주 최저~최고 $2.02 ~ $10.36.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various res
제노티크 바이오사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
제노티크 바이오사이언시즈의 현재 주가는 $2.73 (+10.98%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
제노티크 바이오사이언시즈의 시가총액은 약 $0.01B입니다.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which ar